Back to Agenda
The Changing Landscape of Medical Affairs: Are We Prepared For 2020?
Session Chair(s)
J. Lynn Bass, PharmD, RPh
Medical Affairs Lead
Mesoblast, United States
Approximately twelve years ago, pharmaceutical industry leaders convened to create a 10-year future view for medical affairs with the aim of creating a plan for identifying success in the field. In follow-up, a leading consultant company released a white paper five years later reviewing the progress of the plan. This white paper predicted the following areas would be relevant and the primary focus for Medical Affair’s departments in 2020: innovative therapies, patient-centricity, talent acquisition/training, and integrating disparate streams of medical data and knowledge. However, without a crystal ball, future predictions may be unreliable (even from the leading experts) or subject to the changing regulatory and compliance environment for our industry.
With 2020 just one year away, this session will evaluate progress of the industry in establishing success and expertise in these and other areas and and evaluate new and continuing challenges for Medical Affairs professionals as we move into future decades
Learning Objective : Evaluate the current status of the predictions from the original ‘2020 white paper’ for Medical Affairs departments; Discuss how technology, systems, and organizational models are assisting Medical Affairs departments with their global demands; Evaluate how the evolving regulatory and compliance environment is helping to shape/ morph our Medical Affairs departments and Identify new and emerging areas of focus of the future.
Speaker(s)
Industry Update
Rebecca A. Vermeulen, RPh
Genentech, A Member of the Roche Group, United States
Vice President, Global Patient Networks | PD Medical Affairs
Industry Update
Ann Westra, MD
McKinsey & Company, United States
Senior Medical Knowledge Expert
Have an account?